Proteomics revisits the cancer metabolome

References

• Warburg O. On the origin of cancer cells. Science123(3191), 309–314 (1956).
   PubMed Web of Science ®Google Scholar
• Warburg O. [On the metabolism of the carcinoma cell]. Naturwissenschaften12(50), 1131–1137 (1924).
   Google Scholar
• Zhou ST, Huang CH, Wei YQ. The metabolic switch and its regulation in cancer cells. Sci. China Life Sci.53(8), 942–958 (2010).
   Google Scholar
• Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell9(6), 425–434 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno Sánchez R, Rodríguez Enríquez S, Marín Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J.274(6), 1393–1418 (2007).
   Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature408(6810), 307–310 (2000).
   PubMed Web of Science ®Google Scholar
• Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell Biol.30(6), 1303–1318 (2010).
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev.18(1), 54–61 (2008).
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Pontoglio A, Giardina B. Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin. Appl.4(2), 143–158 (2010).
   PubMed Web of Science ®Google Scholar
• Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer100(9), 1369–1372 (2009).
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science324(5930), 1029–1033 (2009).
   PubMed Web of Science ®Google Scholar
• Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell140(1), 49–61 (2010).
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA104(49), 19345–19350 (2007).
   PubMed Web of Science ®Google Scholar
• Liu R, Li Z, Bai S et al. Mechanism of cancer cell adaptation to metabolic stress. Mol. Cell Proteomics8(1), 70–85 (2009).
   PubMed Web of Science ®Google Scholar
• Ren F, Wu H, Lei Y et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol. Cancer9(1), 81 (2010).
   Google Scholar
• Tong A, Gou L, Lau QC et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J. Proteome. Res.8(2), 1037–1046 (2008).
   Google Scholar
• Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science324(5930), 1076–1080 (2009).
   PubMed Web of Science ®Google Scholar
• Deng H, Yu F, Chen J, Zhao Y, Xiang J, Lin A. Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J. Biol. Chem.283(30), 20754–20760 (2008).
   Google Scholar
• Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends. Biochem. Sci.29(11), 586–592 (2004).
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell134(5), 703–707 (2008).
   PubMed Web of Science ®Google Scholar
• Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal.3(119), ra31 (2010).
   PubMed Web of Science ®Google Scholar
• Li J, Liu R, Lei Y et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy6(6), 711–724 (2010).
   PubMed Web of Science ®Google Scholar
• Ronquist G, Theodorsson E. Inherited, non-spherocytic haemolysis due to deficiency of glucose-6-phosphate dehydrogenase. Scand. J. Clin. Lab. Invest.67(1), 105–111 (2007).
   PubMed Web of Science ®Google Scholar
• Ontko JA. Metabolism of free fatty acids in isolated liver cells. J. Biol. Chem.247(6), 1788–1800 (1972).
   PubMed Web of Science ®Google Scholar
• Mankoff DA, Eary JF, Link JM et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin. Cancer. Res.13(12), 3460–3469 (2007).
   PubMed Web of Science ®Google Scholar
• Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol. Rev.74(4), 993–1026 (1994).
   PubMed Web of Science ®Google Scholar
• Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am. J. Physiol. Endocrinol. Metab.298(2), 141–145 (2010).
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacology Ther.121(1), 29–40 (2009).
   PubMed Web of Science ®Google Scholar
• Thorens B. Molecular and cellular physiology of GLUT-2, a High-Km facilitated diffusion glucose transporter. Int. Rev. Cytol.137, 209–238 (1992).
   Google Scholar
• Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol. Res.35, 9–26 (2002).
   PubMed Web of Science ®Google Scholar
• Christopher CW, Kohlbacher MS, Amos H. Transport of sugars in chick-embryo fibroblasts. Evidence for a low-affinity system and a high-affinity system for glucose transport. Biochem. J.158(2), 439–450 (1976).
   PubMedGoogle Scholar
• Lane RH, Crawford SE, Flozak AS, Simmons RA. Localization and quantification of glucose transporters in liver of growth-retarded fetal and neonatal rats. Am. J. Physiol.276(1), E135–E142 (1999).
   Google Scholar
• Lee JD, Yang WI, Park YN et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J. Nucl. Med.46(10), 1753–1759 (2005).
   Web of Science ®Google Scholar
• Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer. J. Biol. Chem.278(17), 15333–15340 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol.206(12), 2049–2057 (2003).
   PubMed Web of Science ®Google Scholar
• Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res.48(4), 913–919 (1988).
   PubMedGoogle Scholar
• Pedersen PL, Mathupala S, Rempel A, Geschwind J, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta.1555(1–3), 14–20 (2002).
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E. Mitochondrial gateways to cancer. Mol. Aspects. Med.31(1), 1–20 (2010).
   PubMed Web of Science ®Google Scholar
• Parry DM, Pedersen P. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. J. Biol. Chem.258(18), 10904–10912 (1983).
   PubMedGoogle Scholar
• Danial NN, Gramm CF, Scorrano L et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature424(6951), 952–956 (2003).
   PubMed Web of Science ®Google Scholar
• Klimek F, Bannasch P. Isoenzyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis. Carcinogenesis14(9), 1857 (1993).
   Google Scholar
• Rencurel F, Muñoz-Alonso MJ, Girard J, Leturque A. An unusual high-K m hexokinase is expressed in the mhAT3F hepatoma cell line. J. Biol. Chem.273(40), 26187–26193 (1998).
   Google Scholar
• Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc. Natl Acad. Sci. USA74(9), 3735–3739 (1977).
   PubMed Web of Science ®Google Scholar
• Aloj L, Caraco C, Jagoda E, Eckelman W, Neumann R. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res.59(18), 4709–4714 (1999).
   PubMedGoogle Scholar
• Zhao S, Xu W, Jiang W et al. Regulation of cellular metabolism by protein lysine acetylation. Science327(5968), 1000–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Robey R, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene25(34), 4683–4696 (2006).
   PubMed Web of Science ®Google Scholar
• Miller S, Ross-Inta C, Giulivi C. Kinetic and proteomic analyses of S-nitrosoglutathione-treated hexokinase A: consequences for cancer energy metabolism. Amino acids32(4), 593–602 (2007).
   Google Scholar
• Salaris SC, Ramasamy R, Bergmann SR. Fructose-2,6-bisphosphate, a potent stimulator of phosphofructokinase, is increased by high exogenous glucose perfusion. Coron. Artery. Dis.11(3), 279–286 (2000).
   Google Scholar
• Oskam R, Rijksen G, Staal GEJ, Vora S. Isozymic composition and regulatory properties of phosphofructokinase from well-differentiated and anaplastic medullary thyroid carcinomas of the rat. Cancer Res.45(1), 135–142 (1985).
   PubMed Web of Science ®Google Scholar
• Perroud B, Ishimaru T, Borowsky AD, Weiss RH. Grade-dependent proteomics characterization of kidney cancer. Mol. Cell Proteomics8(5), 971–985 (2009).
   PubMed Web of Science ®Google Scholar
• Sánchez-Martínez C, Aragón JJ. Analysis of phosphofructokinase subunits and isozymes in ascites tumor cells and its original tissue, murine mammary gland. FEBS Lett.409(1), 86–90 (1997).
   Google Scholar
• Vora S, Halper JP, Knowles DM. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation-and progression-linked discriminants of malignancy. Cancer Res.45(7), 2993–3001 (1985).
   PubMed Web of Science ®Google Scholar
• Bando H, Atsumi T, Nishio T et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res.11(16), 5784–5792 (2005).
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog.3(1–2), 91–115 (1992).
   Google Scholar
• Marsin AS, Bouzin C, Bertrand L, Hue L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem.277(34), 30778–30783 (2002).
   PubMed Web of Science ®Google Scholar
• Durany N, Joseph J, Jimenez O et al. Phosphoglycerate mutase 2, 3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br. J. Cancer82(1), 20–27 (2000).
   PubMed Web of Science ®Google Scholar
• Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol.23(10), 1303–1307 (2005).
   Google Scholar
• Liu L, Wang S, Zhang Q, Ding Y. Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis. Cell Biol. Int.32(10), 1215–1222 (2008).
   Google Scholar
• Usuba T, Ishibashi Y, Okawa Y, Hirakawa T, Takada K, Ohkawa K. Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. Int. J. Cancer94(5), 662–668 (2001).
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Wang H et al. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl Acad. Sci. USA100(23), 13537–13542 (2003).
   PubMed Web of Science ®Google Scholar
• Li C, Xiao Z, Chen Z et al. Proteome analysis of human lung squamous carcinoma. Proteomics6(2), 547–558 (2006).
   PubMed Web of Science ®Google Scholar
• Narayanan NK, Narayanan BA, Nixon DW. Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect. Prev.28(6), 443–452 (2004).
   Google Scholar
• Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis27(7), 1417–1423 (2006).
   PubMed Web of Science ®Google Scholar
• Fang MZ, Liu C, Song Y et al. Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis25(6), 865–871 (2004).
   Google Scholar
• Kondoh H, Lleonart ME, Gil J et al. Glycolytic enzymes can modulate cellular life span. Cancer Res.65(1), 177–185 (2005).
   PubMed Web of Science ®Google Scholar
• He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics4(10), 3276–3287 (2004).
   PubMed Web of Science ®Google Scholar
• Vorum H, Stergaard M, Hensechke P, Enghild JJ, Riazati M, Rice GE. Proteomic analysis of hyperoxia induced responses in the human choriocarcinoma cell line JEG 3. Proteomics4(3), 861–867 (2004).
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature452(7184), 230–233 (2008).
   PubMed Web of Science ®Google Scholar
• Chen M, David CJ, Manley J. Tumor metabolism: hnRNP proteins get in on the act. Cell Cycle9(10), 1863–1864 (2010).
   PubMed Web of Science ®Google Scholar
• Hacker H, Steinberg P, Bannasch P. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis19(1), 99–107 (1998).
   Google Scholar
• Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol.15(4), 300–308 (2005).
   PubMed Web of Science ®Google Scholar
• Mazurek S, Zwerschke W, Jansen-Dürr P, Eigenbrodt E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem. J.356(Pt 1), 247–256 (2001).
   PubMed Web of Science ®Google Scholar
• Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Dürr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl Acad. Sci. USA96(4), 1291–1296 (1999).
   PubMedGoogle Scholar
• Boxer MB, Jiang J, Vander Heiden MG et al. Evaluation of substituted N,N-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem.53(3), 1048–1055 (2009).
   Google Scholar
• Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A. Akt1 activation can augment hypoxia-inducible factor-1 expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol. Cancer Res.4(7), 471–479 (2006).
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Glossmann H. Glycolysis – one of the keys to cancer? Pharmacol. Sci.1(2), 240–245 (1980).
   Web of Science ®Google Scholar
• Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry44(27), 9417–9429 (2005).
   PubMed Web of Science ®Google Scholar
• Ashizawa K, Willingham M, Liang C, Cheng S. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem.266(25), 16842–16846 (1991).
   PubMed Web of Science ®Google Scholar
• Weernink P, Rijksen G, Staal G. Phosphorylation of pyruvate kinase and glycolytic metabolism in three human glioma cell lines. Tumour Biol.12(6), 339–352 (1991).
   Google Scholar
• Mazurek S, Drexler HCA, Troppmair J, Eigenbrodt E, Rapp ULFR. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res.27(6B), 3963–3971 (2007).
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature452(7184), 181–186 (2008).
   PubMed Web of Science ®Google Scholar
• Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res.67(4), 1602–1608 (2007).
   PubMedGoogle Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab.7(1), 11–20 (2008).
   PubMed Web of Science ®Google Scholar
• Hilf R, Rector WD, Orlando RA. Multiple molecular forms of lactate dehydrogenase and glucose 6-phosphate dehydrogenase in normal and abnormal human breast tissues. Cancer37(4), 1825–1830 (1976).
   Google Scholar
• Unwin RD, Craven RA, Harnden P et al. Proteomic changes in renal cancer and co ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics3(8), 1620–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Leiblich A, Cross S, Catto J et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene25(20), 2953–2960 (2006).
   PubMed Web of Science ®Google Scholar
• Glen A, Gan CS, Hamdy FC et al. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res.7(3), 897–907 (2008).
   PubMed Web of Science ®Google Scholar
• Bui T, Thompson CB. Cancer’s sweet tooth. Cancer Cell9(6), 419–420 (2006).
   PubMed Web of Science ®Google Scholar
• Dang CV. p32 (C1QBP) and cancer cell metabolism: is the Warburg effect a lot of hot air? Mol. Cell Biol.30(6), 1300–1302 (2010).
   PubMed Web of Science ®Google Scholar
• Dai Z, Yin J, He H et al. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics10(21), 3789–3799 (2010).
   PubMed Web of Science ®Google Scholar
• Han J. Mitochondrial alterations in human gastric carcinoma cell line. Am. J. Physiol. Cell Physiol.293(2), 761–771 (2007).
   Google Scholar
• Isidoro A, Martínez M, Fernández PL et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J.378(Pt 1), 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Cuezva JM, Krajewska M, de Heredia ML et al. The bioenergetic signature of cancer. Cancer Res.62(22), 6674–6681 (2002).
   PubMed Web of Science ®Google Scholar
• Matoba S, Kang JG, Patino WD et al. p53 regulates mitochondrial respiration. Science312(5780), 1650–1653 (2006).
   PubMed Web of Science ®Google Scholar
• Cheung EC, Vousden KH. The role of p53 in glucose metabolism. Curr. Opin. Cell Biol.22(2), 186–191 (2010).
   PubMed Web of Science ®Google Scholar
• King A, Selak M, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene25(34), 4675–4682 (2006).
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Weinhouse S. The Warburg hypothesis fifty years later. Z. Krebsforsch Klin. Onkol. Cancer Res. Clin. Oncol.87(2), 115–126 (1976).
   PubMedGoogle Scholar
• Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator–activated receptor- ligands, glucocorticoids, and insulin. Diabetes51(2), 276–283 (2002).
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab.3(3), 187–197 (2006).
   PubMed Web of Science ®Google Scholar
• Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab.3(3), 177–185 (2006).
   PubMed Web of Science ®Google Scholar
• Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev.23(5), 537–548 (2009).
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell13(6), 472–482 (2008).
   PubMed Web of Science ®Google Scholar
• Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation – why mitochondria are targets for cancer therapy. Mol. Aspects Med.31(2), 145–170 (2010).
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Newgard CB. A glucose-to-gene link. Science324(5930), 1021–1022 (2009).
   Google Scholar
• Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol. Metab.21(5), 268–276 (2010).
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr. Biol.19(22), 1046–1052 (2009).
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle8(20), 3243–3245 (2009).
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature458(7239), 762–765 (2009).
   PubMed Web of Science ®Google Scholar
• Morell M, Espargaró A, Avilés FX, Ventura S. Detection of transient protein-protein interactions by bimolecular fluorescence complementation: the Abl-SH3 case. Proteomics7(7), 1023–1036 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RG, Plas DR, Kubek S et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell18(3), 283–293 (2005).
   PubMed Web of Science ®Google Scholar
• Jansen M, ten Klooster JP, Offerhaus GJ, Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol. Rev.89(3), 777–798 (2009).
   PubMed Web of Science ®Google Scholar
• Yocum AK, Chinnaiyan AM. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief. Funct. Genomic. Proteomic.8(2), 145–157 (2009).
   PubMedGoogle Scholar
• Huang WG, Cheng AL, Chen ZC et al. Targeted proteomic analysis of 14-13-3[σ] in nasopharyngeal carcinoma. Int. J. Biochem. Cell Biol.42(1), 137–147 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng L, Pan CX, Zhang JT et al. Loss of 14-13-3σ in prostate cancer and its precursors. Clin. Cancer Res.10(9), 3064–3068 (2004).
   PubMedGoogle Scholar
• Ito K, Suzuki T, Akahira J et al. 14-13-3σ in endometrial cancer – a possible prognostic marker in early-stage cancer. Clin. Cancer Res.11(20), 7384–7391 (2005).
   Google Scholar
• Li Z, Liu JY, Zhang JT. 14-13-3σ, the double-edged sword of human cancers. Am. J. Transl. Res.1(4), 326–340 (2009).
   PubMed Web of Science ®Google Scholar
• Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-13-3 [σ] and other proteins. Semin. Cancer Biol.16(3), 225–234 (2006).
   PubMedGoogle Scholar
• Mhawech P. 14-13-3 proteins – an update. Cell Res.15(4), 228–236 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar V, Annicotte JS, Escote X, Vendrell J, Langin D, Fajas L. Cyclin G2 regulates adipogenesis through PPAR γ coactivation. Endocrinology151(11), 5247–5254 (2010).
   Google Scholar
• Kourtidis A, Srinivasaiah R, Carkner R, Brosnan MJ, Conklin D. Peroxisome proliferator-activated receptor-γ protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res.11(2), R16 (2009).
   PubMed Web of Science ®Google Scholar
• Chearwae W, Bright JJ. PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br. J. Cancer99(12), 2044–2053 (2008).
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nair SA, Pillai MR. Biology of PPAR γ in cancer: a critical review on existing lacunae. Curr. Mol. Med.7(6), 532–540 (2007).
   PubMed Web of Science ®Google Scholar
• Alevizos I, Mahadevappa M, Zhang X et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene20(43), 6196–6204 (2001).
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology144(10), 4562–4574 (2003).
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshida H, Uruno T et al. Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. Anticancer Res.23(3B), 2335–2338 (2003).
   Google Scholar
• Choi MG, Noh JH, An JY et al. Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression. J. Surg. Res.157(2), 168–174 (2009).
   PubMed Web of Science ®Google Scholar
• Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res.64(24), 8980–8986 (2004).
   PubMedGoogle Scholar
• Gerstein M, Lan N, Jansen R. Integrating interactomes. Science295(5553), 284–287 (2002).
   PubMedGoogle Scholar
• Pilot-Storck F, Chopin E, Rual JF et al. Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol. Cell Proteomics9(7), 1578–1593 (2010).
   PubMed Web of Science ®Google Scholar
• Brunn GJ, Hudson CC, Sekuli A et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science277(5322), 99–101 (1997).
   PubMed Web of Science ®Google Scholar
• Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl Acad. Sci. USA95(4), 1432–1437 (1998).
   PubMed Web of Science ®Google Scholar
• Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes53(Suppl. 3), S225–S232 (2004).
   PubMed Web of Science ®Google Scholar
• Mori H, Inoki K, Münzberg H et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab.9(4), 362–374 (2009).
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Kosmatka M, Bardeesy N et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA101(10), 3329–3335 (2004).
   PubMed Web of Science ®Google Scholar
• Davies SP, Sim ATR, Hardie DG. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur. J. Biochem.187(1), 183–190 (1990).
   PubMedGoogle Scholar
• Greer EL, Oskoui PR, Banko MR et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem.282(41), 30107–30119 (2007).
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. USA102(23), 8204–8209 (2005).
   PubMed Web of Science ®Google Scholar
• Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer10(5), 342–352 (2010).
   PubMed Web of Science ®Google Scholar
• Chen X, Thakkar H, Tyan F et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene20(42), 6073–6083 (2001).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Magrini E, Ceresoli GL et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst.96(15), 1133–1141 (2004).
   PubMed Web of Science ®Google Scholar
• Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res.61(2), 589–593 (2001).
   PubMed Web of Science ®Google Scholar
• Page C, Huang M, Jin X et al. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. J. Oncol.17(1), 23–28 (2000).
   PubMed Web of Science ®Google Scholar
• Porstmann T, Griffiths B, Chung YL et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene24(43), 6465–6481 (2005).
   PubMed Web of Science ®Google Scholar
• Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal.21(5), 656–664 (2009).
   PubMed Web of Science ®Google Scholar
• David Z, Fei Y, Ling G et al. Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div.4, 20 (2009).
   Google Scholar
• Madoz-Gúrpide J, Cañamero M, Sanchez L, Solano J, Alfonso P, Casal JI. A proteomics analysis of cell signaling alterations in colorectal cancer. Mol. Cell Proteomics6(12), 2150 (2007).
   PubMed Web of Science ®Google Scholar
• Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J. Cell Biochem.106(6), 1113–1122 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou C, Qiu L, Sun Y et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA’s effect on cell death and migration in human ovarian cancer cells. Int. J. Oncol.29(1), 269–278 (2006).
   PubMed Web of Science ®Google Scholar
• Toulany M, Baumann M, Rodemann HP. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol. Cancer Res.5(8), 863–872 (2007).
   PubMed Web of Science ®Google Scholar
• Monga SPS. Role of Wnt/[β]-catenin signaling in liver metabolism and cancer. Int. J. Biochem. Cell Biol.43(7), 1021–1029 (2011).
   PubMed Web of Science ®Google Scholar
• Brase JC, Mannsperger H, Fröhlich H et al. Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci.8(1), 36 (2010).
   Google Scholar
• Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol.168(1), 93–103 (2006).
   PubMed Web of Science ®Google Scholar
• Nice E, Rothacker J, Weinstock J, Lim L, Catimel B. Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis. J. Chromatogr. A.1168(1–2), 190–210 (2007).
   PubMed Web of Science ®Google Scholar
• Ang CS, Phung J, Nice EC. The discovery and validation of colorectal cancer biomarkers. Biomed. Chromatogr.25(1–2), 82–99 (2011).
   PubMed Web of Science ®Google Scholar
• Murphy JP, Pinto DM. Targeted proteomic analysis of glycolysis in cancer cells. J. Proteome Res.10(2), 604–613 (2011).
   Google Scholar
• Kolch W, Pitt A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer10(9), 618–629 (2010).
   PubMed Web of Science ®Google Scholar
• Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jørgensen TJD. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell Proteomics4(7), 873–886 (2005).
   PubMed Web of Science ®Google Scholar
• Pinkse MWH, Uitto PM, Hilhorst MJ, Ooms B, Heck AJR. Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Anal. Chem.76(14), 3935–3943 (2004).
   PubMed Web of Science ®Google Scholar
• Tao WA, Wollscheid B, O’Brien R et al. Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry. Nat. Methods2(8), 591–598 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou H, Watts JD, Aebersold R. A systematic approach to the analysis of protein phosphorylation. Nat. Biotechnol.19(4), 375–378 (2001).
   PubMed Web of Science ®Google Scholar
• Ding SJ, Qian WJ, Smith RD. Quantitative proteomic approaches for studying phosphotyrosine signaling. Expert Rev. Proteomics4(1), 13–23 (2007).
   PubMed Web of Science ®Google Scholar
• McNulty DE, Annan RS. Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol. Cell Proteomics7(5), 971–980 (2008).
   PubMed Web of Science ®Google Scholar
• Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol.7(12), 952–958 (2006).
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics3(12), 1154–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Leroy C, Fialin C, Sirvent A et al. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res.69(6), 2279–2286 (2009).
   PubMedGoogle Scholar
• Yan GR, Chen NP, Huang YD et al. Signaling networks in gastric cancer cells revealed by phosphoproteomics. J. Proteomics. Bioinform.3(4), 113–120 (2010).
   Google Scholar
• Moritz A, Li Y, Guo A et al. Akt-RSK-S6 Kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal.3(136), ra64 (2010).
   PubMed Web of Science ®Google Scholar
• Andersen JN, Sathyanarayanan S, Di Bacco A et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med.2(43), 43ra55 (2010).
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell131(6), 1190–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Kinch MS, Moore MB, Harpole DH. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res.9(2), 613–618 (2003).
   PubMed Web of Science ®Google Scholar
• Amann J, Kalyankrishna S, Massion PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res.65(1), 226–235 (2005).
   PubMed Web of Science ®Google Scholar
• Stephens P, Hunter C, Bignell G et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature431(7008), 525–526 (2004).
   PubMed Web of Science ®Google Scholar
• Cheung WL, Briggs SD, Allis CD. Acetylation and chromosomal functions. Curr. Opin. Cell Biol.12(3), 326–333 (2000).
   PubMed Web of Science ®Google Scholar
• Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends. Cell Biol11(6), 266–273 (2001).
   PubMed Web of Science ®Google Scholar
• Yang X, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene26(37), 5310–5318 (2007).
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science325(5942), 834–840 (2009).
   PubMed Web of Science ®Google Scholar
• Shulaev V. Metabolomics technology and bioinformatics. Brief Bioinform.7(2), 128–139 (2006).
   PubMed Web of Science ®Google Scholar
• Hekmatyar S, Wilson M, Jerome N et al.1H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice. Br. J. Cancer103(8), 1297–1304 (2010).
   PubMedGoogle Scholar
• Crawford D, Serkova N, Gamito E, Jones R, O’Donnell C, Hedlund T. Nuclear magnetic resonance spectroscopy of expressed prostatic secretions: metabolite citrate and derivatives are potential markers of prostate cancer. J. Clin. Oncol.24(18), 4623 (2006).
   Google Scholar
• Denkert C, Budczies J, Weichert W et al. Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover. Mol. Cancer7(1), 72 (2008).
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature457(7231), 910–914 (2009).
   PubMed Web of Science ®Google Scholar
• Lawton KA, Berger A, Mitchell M et al. Analysis of the adult human plasma metabolome. Pharmacogenomics9(4), 383–397 (2008).
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Tomlins SA et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia9(5), 443–454 (2007).
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Mehra R, Rhodes DR et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet.39(1), 41–51 (2006).
   Google Scholar
• Kelloff GJ, Hoffman JM, Johnson B et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res.11(8), 2785–2808 (2005).
   PubMed Web of Science ®Google Scholar
• Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl. Med. Biol.28(1), 1–4 (2001).
   PubMed Web of Science ®Google Scholar
• Aderem A. Systems biology: its practice and challenges. Cell121(4), 511–513 (2005).
   PubMed Web of Science ®Google Scholar
• Boros LG, Serkova NJ, Cascante MS, Lee WNP. Use of metabolic pathway flux information in targeted cancer drug design. Drug Discov. Today Ther. Strateg.1(4), 435–443 (2004).
   Google Scholar
• Green R. Mystery of thiamine-responsive megaloblastic anemia unlocked. Blood102(10), 3464–3465 (2003).
   Google Scholar
• Harris T, Eliyahu G, Frydman L, Degani H. Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells. Proc. Natl Acad. Sci. USA106(43), 18131–18136 (2009).
   PubMed Web of Science ®Google Scholar
• Vazquez A, Liu J, Zhou Y, Oltvai ZN. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC. Syst. Biol.4(1), 58 (2010).
   PubMed Web of Science ®Google Scholar
• Schaffer JE. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol.14(3), 281–287 (2003).
   PubMed Web of Science ®Google Scholar
• Artwohl M, Roden M, Waldhäusl W, Freudenthaler A, Baumgartner-Parzer SM. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB. J.18(1), 146–148 (2004).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Chan C. Application of metabolic flux analysis to identify the mechanisms of free fatty acid toxicity to human hepatoma cell line. Biotechnol. Bioeng.99(2), 399–410 (2008).
   PubMed Web of Science ®Google Scholar
• Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochim. Biophys. Acta1801(3), 381–391 (2010).
   PubMed Web of Science ®Google Scholar
• Boros LG, Lerner MR, Morgan DL et al. [1,2-13C2]-D-glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. Pancreas31(4), 337–343 (2005).
   PubMedGoogle Scholar
• Yang C, Richardson AD, Osterman A, Smith JW. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics4(1), 13–29 (2008).
   Google Scholar
• Munger J, Bennett BD, Parikh A et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol.26(10), 1179–1186 (2008).
   PubMed Web of Science ®Google Scholar
• Na TY, Shin YK, Roh KJ et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology49(4), 1122–1131 (2009).
   PubMedGoogle Scholar
• Huttlin EL, Chen X, Barrett-Wilt GA et al. Discovery and validation of colonic tumor-associated proteins via metabolic labeling and stable isotopic dilution. Proc. Natl Acad. Sci. USA106(40), 17235–17240 (2009).
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer4(7), 551–561 (2004).
   PubMed Web of Science ®Google Scholar
• Shi H, Wei SH, Leu YW et al. Triple Analysis of the Cancer Epigenome. Cancer Res.63(9), 2164–2171 (2003).
   PubMed Web of Science ®Google Scholar
• Feltus F, Lee E, Costello J, Plass C, Vertino P. Predicting aberrant CpG island methylation. Proc. Natl Acad. Sci. USA100(21), 12253–12258 (2003).
   PubMed Web of Science ®Google Scholar
• Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet.12(2), R145–R152 (2003).
   PubMed Web of Science ®Google Scholar
• Roy NC, Altermann E, Park ZA, McNabb WC. A comparison of analog and next-Generation transcriptomic tools for mammalian studies. Brief. Funct. Genomics10(3), 135–150 (2011).
   Google Scholar
• Chin K, DeVries S, Fridlyand J et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell10(6), 529–541 (2006).
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell10(6), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis18(3–4), 533–537 (1997).
   PubMed Web of Science ®Google Scholar
• Hanash S. Disease proteomics. Nature422(6928), 226–232 (2003).
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell31(4), 449–461 (2008).
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Tseng A, Gao D et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(β-TRCP) ubiquitin ligase. Cancer Cell18(2), 147–159 (2010).
   PubMed Web of Science ®Google Scholar
• Tateishi Y, Ariyoshi M, Igarashi R et al. Molecular basis for SUMOylation-dependent regulation of DNA binding activity of heat shock factor 2. J. Biol. Chem.284(4), 2435–2447 (2009).
   Google Scholar
• Mani A, Gelmann EP. The ubiquitin–proteasome pathway and its role in cancer. J. Clin. Oncol.23(21), 4776–4789 (2005).
   PubMed Web of Science ®Google Scholar
• Nishizuka S, Charboneau L, Young L et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA100(24), 14229–14234 (2003).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Salas S, Eysteries S et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene23(7), 1377–1391 (2004).
   PubMed Web of Science ®Google Scholar
• Bi X, Lin Q, Foo TW et al. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways. Mol. Cell Proteomics5(6), 1119–1130 (2006).
   PubMed Web of Science ®Google Scholar
• Hurt EM, Thomas SB, Peng B, Farrar WL. Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood109(9), 3953–3962 (2007).
   PubMed Web of Science ®Google Scholar
• Liu R, Wang K, Yuan K, Wei Y, Huang C. Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev. Proteomics7(3), 411–429 (2010).
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao JS, Li JJ et al. A combined proteomic and metabolomic profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol. Cell Proteomics9(12), 2617–2618 (2010).
   PubMed Web of Science ®Google Scholar
• Perroud B, Lee J, Valkova N et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer5(1), 64 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi G, Xia W et al. Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res.64(20), 7302–7310 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang DH, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ESC. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell Proteomics4(11), 1686–1696 (2005).
   PubMed Web of Science ®Google Scholar
• Li LS, Kim H, Rhee H et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics4(11), 3394–3400 (2004).
   PubMed Web of Science ®Google Scholar
• Sun W, Xing B, Sun Y et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis. Mol. Cell Proteomics6(10), 1798–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Xu X, Qiao M, Zhang Y et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: Discovery of TIMM17A as a marker for breast cancer. Proteomics10(7), 1374–1390 (2010).
   PubMed Web of Science ®Google Scholar
• McKinney KQ, Lee YY, Choi HS et al. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J. Proteomics74(1), 79–88 (2010).
   Google Scholar
• Nibbe RK, Markowitz S, Myeroff L, Ewing R, Chance MR. Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol. Cell Proteomics8(4), 827–845 (2009).
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Huang CC et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res.8(7), 2298–2305 (2002).
   PubMed Web of Science ®Google Scholar
• Tomonaga T, Matsushita K, Yamaguchi S et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res.10(6), 2007–2014 (2004).
   PubMed Web of Science ®Google Scholar